News
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it. | Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy,
Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race
FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the agency and pharma industry; Roche and Regeneron jump on the U.S. manufacturing train as Trump’s tariffs loom;
Zacks Investment Research on MSN16h
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...
Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...
Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...
which was a significant improvement on Novo Nordisk's main marketed obesity drug – Wegovy – which is based on semaglutide alone. Novo Nordisk emphasised an interpretation of the data ...
Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...
Texas-based Lexicon has been studying LX9851 as a standalone therapy and in combination with GLP-1 agonists such as semaglutide, the main ingredient in Novo Nordisk’s Wegovy. At the Obesity ...
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive pressure ...
Preclinical data presented at Obesity Week in Texas, US in November 2024 suggested that combining LX9851 with Novo Nordisk’s flagship drug semaglutide, marketed as Ozempic in type 2 diabetes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback